BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm

Investors have until December 21, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, October 28, 2021
Information
Tags: 
Legal, Professional Services, Loss, Court, BMRN, BioMarin Pharmaceutical, BMN, Person, NASDAQ, Complaint, FDA, Telephone, P.C, Company, District court, Jeanne Eagels
Geotags: 
NEW YORK, United States, NORTHERN DISTRICT, CALIFORNIA, SOUTH CAROLINA
⚠ generated by AI ↴
Organisation: 
BRAGAR EAGEL & SQUIRE, P.C.
Summary
Key Points: 
  • Investors have until December 21, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • is a nationally recognized law firm with offices in New York, California, and South Carolina.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.


Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against BioMarin Pharmaceuticals (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired BioMarin securities between January 1, 2020 and September 3, 2021, both dates inclusive (the “Class Period”). Investors have until December 21, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

According to the filed complaint: (i) BMN 307 was less safe than BioMarin had led investors to believe; (ii) BMN 307’s safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307’s clinical and commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you purchased or otherwise acquired BioMarin shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright: 
Copyright Business Wire 2021